Who
Keith R. Leonard
Director
Company insider
Files Form 4 as: Director, Arcutis Biotherapeutics; Director, Intuitive Surgical; Chief Executive Officer, Unity Biotechnology; Director, Sienna Biopharmaceuticals; Director, Anacor Pharmaceuticals; President & CEO, Kythera Biopharmaceuticals; Director, Affymax; Director, ARYx Therapeutics.
In numbers
- Trades disclosed
- 240
- Buys
- 2
- Sells
- 45
- Bought
- $501K
- Sold
- $16.2M
- Companies
- 8
- Companies where not an officer
- 6
- First trade
- 7 Nov 2007
- Last trade
- 5 Jun 2026
- Last filed
- 9 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Jun 2026filed 9 Jun 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —5,778 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,667 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,667 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —5,778 at $0.00 | filing |
| 30 Apr 2026filed 30 Apr 2026 | ISRG Intuitive SurgicalMedical Devices | SEC FORM 4 Code M | —531 at $0.00 | filing |
| 30 Apr 2026filed 30 Apr 2026 | ISRG Intuitive Surgicaloption or derivative · Medical Devices | SEC FORM 4 Code M | —531 at $0.00 | filing |
| 30 Apr 2026filed 30 Apr 2026 | ISRG Intuitive Surgicaloption or derivative · Medical Devices | SEC FORM 4 Code A | —554 at $0.00 | filing |
| 30 Apr 2026filed 30 Apr 2026 | ISRG Intuitive Surgicaloption or derivative · Medical Devices | SEC FORM 4 Code M | —531 at $0.00 | filing |
| 30 Apr 2026filed 30 Apr 2026 | ISRG Intuitive Surgicaloption or derivative · Medical Devices | SEC FORM 4 Code A | —554 at $0.00 | filing |
| 30 Apr 2026filed 30 Apr 2026 | ISRG Intuitive SurgicalMedical Devices | SEC FORM 4 Code M | —531 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code M | $233K27,052 at $8.63 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code M | $92K12,220 at $7.51 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $997K39,272 at $25.39 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —27,052 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —12,220 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —27,052 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —12,220 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code M | $233K27,052 at $8.63 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code M | $92K12,220 at $7.51 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $997K39,272 at $25.39 | filing |
News
Arcutis Biotherapeutics (ARQT) Gets New Rating Uprgades from 2 Analysts; Shares ClimbARQT · insidermonkey.com · 20 Oct 2026Arcutis Biotherapeutics advances 11% to new 52-week high (ARQT:NASDAQ)ARQT · seekingalpha.com · 19 Oct 2026
0 headlines in the last 90 days name Keith R. Leonard; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.